Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The Family-ICU Trial is a research study that aims to see if including family members in the daily rounds of care for patients in the intensive care unit (ICU) can improve how engaged families feel in their loved one's care. This study is important because while experts recommend involving families in ICU rounds, many hospitals do not do this regularly. The trial will look at whether family participation helps reduce their anxiety and depression, makes them more satisfied with the care their loved ones receive, and explores how to better include family members in these discussions.
To participate, family members must be at least 18 years old and have a loved one in the ICU who is expected to stay for at least 48 hours. They should also be comfortable using technology like a phone or computer to join the rounds virtually. The study is currently recruiting participants at six different ICUs in Canada. Family members who choose to take part can expect to engage with the healthcare team about their loved one’s care through virtual meetings, helping to create a more family-centered approach in the ICU.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult family members (age ≥ 18 years) of ICU patients
- • Expected ICU stay ≥ 48 hours
- • Family members wishing to participate in rounds virtually must have the technological capability and understanding to participate virtually (must have a phone or computer with internet and audio/video capabilities)
- Exclusion Criteria:
- • Family members who do not wish to participate in care
- • Repeat admissions within the study period
- • Another family member has already participated in the study
About Lady Davis Institute
The Lady Davis Institute (LDI) is a leading Canadian research organization dedicated to advancing health sciences through innovative clinical trials and translational research. Affiliated with the Jewish General Hospital in Montreal, LDI focuses on a multidisciplinary approach to understanding disease mechanisms and developing effective therapies. With a commitment to improving patient outcomes, the institute collaborates with academic institutions and industry partners to drive breakthroughs in areas such as cancer, cardiovascular health, and chronic diseases. Through its rigorous research programs and adherence to ethical standards, the Lady Davis Institute aims to contribute significantly to the global scientific community and enhance the quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
Michael J Goldfarb, MD, MSc
Principal Investigator
Lady Davis Institute, McGill University, Jewish General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported